Emerging treatment strategies for glioblastoma multiforme

Steven K. Carlsson, Shaun P. Brothers, Claes Wahlestedt

Research output: Contribution to journalReview articlepeer-review

170 Scopus citations


Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5-year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small-molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population. A comprehensive overview and discussion of our current understanding of glioblastoma multiforme (GBM) pathophysiology and heterogeneity, diagnostic techniques and treatment options, including novel therapies such as monoclonal antibodies and small-molecule inhibitors.

Original languageEnglish (US)
Pages (from-to)1359-1370
Number of pages12
JournalEMBO Molecular Medicine
Issue number11
StatePublished - Nov 1 2014


  • Biomarkers
  • Brain imaging
  • Cancer stem cells
  • Epigenetics
  • Glioblastoma multiforme (GBM)


Dive into the research topics of 'Emerging treatment strategies for glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this